SOURCE: Prana Biotechnology

September 20, 2007 11:23 ET

Prana Co-Founding Scientist, Professor Rudolph Tanzi, to Participate in Alzheimer's Association Expert Panel Discussion

Panel to Address "Competing Paradigms in Alzheimer's Research"

MELBOURNE, AUSTRALIA--(Marketwire - September 20, 2007) - Prana Biotechnology Limited (NASDAQ: PRAN) (ASX: PBT), a biopharmaceutical company focused on the research and development of treatments for neurodegenerative disorders, today announced that Rudolph E. Tanzi, Ph.D., Co-Founding Scientist of Prana Biotechnology, together with other distinguished medical and scientific experts, will participate in a panel discussion at the Alzheimer's Association New York City Chapter's 20th Annual Meeting, at 6:00 p.m. on September 25, 2007.

The panel, titled "Competing Paradigms in Alzheimer's Research," will offer an informative discussion on diverse views in the search for the cure.

Prana co-founding scientists' theories concerning the interaction between metals and the protein beta-amyloid in the brain are the basis of Prana's treatments for Alzheimer's and other neurodegenerative diseases. Prana's proprietary lead compound, PBT2, is currently in a Phase IIa clinical trial for patients with early Alzheimer's disease. The trial is progressing well, with patient dosing on track to be completed by the end of 2007.

The panel discussion will take place at The Rockefeller University - Caspary Auditorium and is open to the public. For further details of the panel, visit the Alzheimer's Association website www.alznyc.org.

About Prana Biotechnology Limited

Prana Biotechnology was established to commercialize research into Alzheimer's disease and other major age-related neurodegenerative disorders. The company was incorporated in 1997 and listed on the Australian Stock Exchange in March 2000 and listed on NASDAQ in September 2002. Researchers at prominent international institutions including The University of Melbourne, The Mental Health Research Institute (Melbourne) and Massachusetts General Hospital, a teaching hospital of Harvard Medical School, contributed to the discovery of Prana's technology.

For further information, please visit our web site at www.pranabio.com.

Contact Information